|
Oct 9
|
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
|
|
Jul 26
|
We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
|
|
Jun 20
|
Spirit Aero downgraded, Skyworks upgraded: Wall Street's top analyst calls
|
|
May 9
|
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
|
|
May 7
|
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
Apr 13
|
Several Insiders Invested In Prelude Therapeutics Flagging Positive News
|
|
Apr 9
|
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
|
|
Mar 5
|
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
|
|
Jan 14
|
Prelude Therapeutics Incorporated (NASDAQ:PRLD) is definitely on the radar of hedge funds investors who own 33% of the company
|
|
Jan 2
|
Shell (SHEL) Resumes LNG Loading From Prelude Facility
|
|
Nov 28
|
Shell's (SHEL) Prelude LNG Facility to Restart in December
|
|
Apr 27
|
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May
|